Arrowhead Pharmaceuticals has completed patient enrolment in the global Phase III YOSEMITE study of zodasiran, an investigational treatment for HoFH.

The post Arrowhead concludes enrolment for Phase III zodasiran trial in HoFH appeared first on Clinical Trials Arena.